Tesla Expands Affordable Model 3 Lineup in Europe to Boost EV Demand 
Netflix’s Bid for Warner Bros Discovery Aims to Cut Streaming Costs and Reshape the Industry 
Spain’s Industrial Output Records Steady Growth in October Amid Revised September Figures 
Oil Prices Hold Steady as Ukraine Tensions and Fed Cut Expectations Support Market 
Japan’s Nikkei Drops as Markets Await Key U.S. Inflation Data 
South Korea Posts Stronger-Than-Expected 1.3% Economic Growth in Q3 
Asian Markets Mixed as Fed Rate Cut Bets Grow and Japan’s Nikkei Leads Gains 
Amazon Italy Pays €180M in Compensation as Delivery Staff Probe Ends 
USPS Expands Electric Vehicle Fleet as Nationwide Transition Accelerates 
Proxy Advisors Urge Vote Against ANZ’s Executive Pay Report Amid Scandal Fallout 
China’s Services Sector Posts Slowest Growth in Five Months as Demand Softens 
Asian Currencies Edge Higher as Markets Look to Fed Rate Cut; Rupee Steadies Near Record Lows 
Michael Dell Pledges $6.25 Billion to Boost Children’s Investment Accounts Under Trump Initiative 
IKEA Expands U.S. Manufacturing Amid Rising Tariffs and Supply Chain Strategy Shift 
ExxonMobil to Shut Older Singapore Steam Cracker Amid Global Petrochemical Downturn 
Citi Sets Bullish 2026 Target for STOXX 600 as Fiscal Support and Monetary Easing Boost Outlook 
Dollar Holds Steady as Markets Shift Focus to 2026 Rate Cut Expectations 
Samsung Electronics’s executive chairman, Lee Jae Yong, has been holding meetings with leaders of the leading biopharmaceutical and biotechnology companies to forge joint ventures or enter into partnership deals.
The Samsung Electronics chief reportedly met up with global executives of some leading brands in the biotech and biopharma industry, including Johnson & Johnson’s chief executive officer, Joaquin Duato; Biogen’s chief, Christopher Viehbacher; Bristol Myers Squibb’s CEO, Giovanni Caforio; Kevin Ali, Organon’s CEO; and Noubar Afeyan of Flagship Pioneering.
Lee held meetings with them during his recent trip to the United States. Korea Joongang Daily reported that the Samsung leader has a goal of securing partnership agreements with them as he is seeing the biopharma and biotech fields as the company’s new growth drivers.
The Samsung chairman also commented during his trip, "The starting point is not important, but bold and persistent challenges set victory apart from defeat. Let us continue the success story of chips with bio."
In any case, Lee Jae Yong is trying to get contracts for the company’s CMDO arm, Samsung Biologics, which is currently the largest contract manufacturing and development organization in the world based on production capacity.
While it is a latecomer in this market, Samsung Biologics is doing fairly well since it was first established in 2011. Samsung Electronics owns 31.22% of shares in its affiliate CMDO firm.
"The bio-industry is a field with high barriers to entry, requiring not only production technology and R&D capabilities but also trust and reputation building for long-term collaboration,” The Korea Times quoted Samsung as saying in a statement regarding the chairman's move to seek collaborations with US bio companies. “Lee's wide global network is expected to serve as a lever for Samsung's bio business to expand collaboration with big pharmaceutical companies and create future growth opportunities."
